Recruiting

Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients

This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmonary arterial hypertension patients

ClinicalTrials.gov IDNCT07149935
PhaseNA
Enrollment104
SponsorRenJi Hospital
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Pulmonary Hypertension

About this study

This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmonary arterial hypertension patients

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: 1. Patients who suffered from pre-capillary PAH (mPAP ≥ 20 mmHg, PVR \> 2 Woods unit, PAWP ≤ 15 mmHg) confirmed by right heart catheterisation. 2. Patients who are in the status of WHO-FC I-III. 3. Patients between 18 and 75 years old 4. Female subjects are not pregnant. 5. Patients are treated with PAH-targeted drugs and are in a stable state and there is no progress of disease). 6. Patients have not received exercise rehabilitation training within six months. Exclusion Criteria: Patients with the following diseases or symptoms: 1. Pulmonary vascular occlusive disease 2. Respiratory diseases 3. Ischaemic heart disease, complex congenital heart disease (e.g., tetralogy of Fallot, etc.), cardiomyopathy, valvular disease 4. Active liver disease 5. Severe kidney disease 6. Motor disorders (e.g. lower limb fracture, ataxia, etc.) 7. Malignant tumour diseases 8. Physical disability 9. Hb ≤ 80g / L 10. Systolic blood pressure ≤85mmHg 11. History of syncope within 3 months 12. History of supraventricular or ventricular arrhythmia at rest within 3 months.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.